Swedish Orphan Biovitrum AB (publ)·Healthcare
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Healthcare
Drug Manufacturers - Specialty & Generic
1,895
2021-01-08
0.23

STOCKHOLM, March 27, 2026 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Wednesday, 6 May 2026 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript

Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) and Astria Therapeutics (NASDAQ: ATXS - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Valuation and Earnings This table compares Swedish